Specific IKKβ inhibitor IV blocks streptonigrin-induced NF-κB activity and potentiates its cytotoxic effect on cancer cells

Molecular Carcinogenesis

Volumn 48, Issue 8, 2009, Pages 678-684

  Gavriil, Maria ^a   Tsao, Cheng Chung ^a   Mandiyan, Sreekala ^a   Arndt, Kim ^a   Abraham, Robert ^a   Zhang, Yixian ^a,b  

^a WYETH RESEARCH   (United States)

^b Enzon Pharmaceuticals   (United States)

Author keywords

DNA damage; IKK; NF B; NQO1; Pancreatic cancer; Streptonigrin

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DICOUMAROL; HYDROQUINONE; I KAPPA B ALPHA; I KAPPA B KINASE BETA INHIBITOR IV; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE QUINONE OXIDOREDUCTASE; RUFOCROMOMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CASPASE; ENZYME INHIBITOR; H2AFX PROTEIN, HUMAN; HISTONE; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MELANOMA; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CASPASES; CELL PROLIFERATION; DNA DAMAGE; ENZYME INHIBITORS; HISTONES; HUMANS; I-KAPPA B KINASE; MELANOMA; NAD(P)H DEHYDROGENASE (QUINONE); NF-KAPPA B; PANCREATIC NEOPLASMS; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; STREPTONIGRIN; TUMOR CELLS, CULTURED;

EID: 68849105817     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20550     Document Type: Article

References (30)

1. Marsh W, Garretson A, Wesel E. Streptonigrin, an antitumor agent produced by strains of Streptomyces flocculus. I. Microbiological studies. Antibiot Chemother 1961;11:151-157.
2. Bolzan AD, Bianchi MS. Genotoxicity of streptonigrin: A review. Mutat Res 2001;488:25-37.
3. Cone R, Hasan SK, Lown JW, Morgan AR. The mechanism of the degradation of DNA by streptonigrin. Can J Biochem 1976;54:219-223.
4. DeGraff W, Hahn SM, Mitchell JB, Krishna MC. Free radical modes of cytotoxicity of adriamycin and streptonigrin. Biochem Pharmacol 1994;48:1427-1435. (Pubitemid 24318148)
5. Lown JW, Sim SK, Chen HH. Hydroxyl radical production by free and DNA-bound aminoquinone antibiotics and its role in DNA degradation. Electron spin resonance detection of hydroxyl radicals by spin trapping. Can J Biochem 1978;56: 1042-1047.
6. Shiloh Y, Tabor E, Becker Y. Abnormal response of ataxiatelangiectasia cells to agents that break the deoxyribose moiety of DNA via a targeted free radical mechanism. Carcinogenesis 1983;4:1317-1322. (Pubitemid 14229463)
7. Sugiura Y, Kuwahara J, Suzuki T. DNA interaction and nucleotide sequence cleavage of copper-streptonigrin. Biochim Biophys Acta 1984;782:254-261. (Pubitemid 14089854)
8. Yamashita Y, Kawada S, Fujii N, Nakano H. Induction of mammalian DNA topoisomerase II dependent DNA cleavage by antitumor antibiotic streptonigrin. Cancer Res 1990;50: 5841-5844. (Pubitemid 20331387)
9. Capranico G, Palumbo M, Tinelli S, Zunino F. Unique sequence specificity of topoisomerase II DNA cleavage stimulation and DNA binding mode of streptonigrin. J Biol Chem 1994;269:25004-25009. (Pubitemid 24311767)
10. Cusack J, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappa B inhibition. Cancer Res 2001; 61:3535-3540. (Pubitemid 32694955)
11. Bottero V, Busuttil V, Loubat A, et al. Activation of nuclear factor kappa B through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: A brake to apoptosis in HeLa human carcinoma cells. Cancer Res 2001; 61:7785-7791. (Pubitemid 33049365)
12. Piret B, Piette J. Topoisomerase poisons activate the transcription factor NF-kappa-B in ACH-2 and CEM cells. Nucleic Acids Res 1996;24:4242-4248. (Pubitemid 26377342)
13. Yeh P, Chuang S, Yeh K, Song Y, Ea C, Cheng A. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol 2002;63:1423-1430. (Pubitemid 34457957)
14. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. P53 stabilization is decreased upon NF kappa B activation: A role for NF kappa B in acquisition of resistance to chemotherapy. Cancer Cell 2002;1:493-503. (Pubitemid 41039129)
15. Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma I. I kappa B kinase-independent I kappa Ba degradation pathway: Functional NF-kappa B activity and implications for cancer therapy. Mol Cell Biol 2003;23:8070-8083. (Pubitemid 37377499)
16. Nakanishi C, Toi M. Nuclear factor-kappa B inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309. (Pubitemid 40488635)
17. Panta G, Kaur S, Cavin L, et al. ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappa B through a common MEK extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage. Mol Cell Biol 2004;24:1823-1835.
18. Li N, Banin S, Quyang H, et al. ATM is required for I kappa B kinase (IKK) activation in response to DNA double strand breaks. J Biol Chem 2001;276:8898-8903. (Pubitemid 37385464)
19. Wu Z-H, Shi Y, Tibbetts RS, Miyamoto S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 2006;311:1141-1146. (Pubitemid 43305951)
20. Huang TT, Wuerzberger-Davis SM, Wu Z-H, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 2003;115:565-576. (Pubitemid 37506045)
21. Janssens S, Tinel A, Lippens S, Tschopp J. PIDD mediates NF-kappa B activation in response to DNA damage. Cell 2005;123:1079-1092. (Pubitemid 41785422)
22. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-kappa B activity. Annu Rev Immunol 2000;18:621-663. (Pubitemid 30365393)
23. Karin M. Nuclear factor-kappa B in cancer development and progression. Nature 2006;441:431-436. (Pubitemid 44050137)
24. Podolin PL, Callahan JF, Bolognese BJ, et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB kinase 2, TPCA- 1 (2-((aminocarbonyl)amino)-5-(4- fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J Pharmacol Exp Ther 2005;312:373-381.
25. Pernin D, Bay JO, Uhrhammer N, Bignon YJ. ATM heterozygote cells exhibit intermediate levels of apoptosis in response to streptonigrin and etoposide. Eur J Cancer 1999;35:1130-1135. (Pubitemid 29339198)
26. Sun X, Ross D. Quinone-induced apoptosis in human colon adenocarcinoma cells via DT-diaphorase mediated bioactivation. Chem Biol Interact 1996;100:267-276. (Pubitemid 126334327)
27. Wang H, Yeo SL, Xu J, et al. Isolation of streptonigrin and its novel derivative from Micromonospora as inducing agents of p53-dependent cell apoptosis. J Nat Prod 2002;65:721-724. (Pubitemid 34547417)
28. Logsdon C, Simeone D, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003;63:3445.
29. Lewis A, Ough M, Hinkhouse M, Tsao M, Oberley L, Cullen J. Targeting NAD(P)H: Quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog 2005;43:215-224.
30. Gu B, DeAngelis LM. Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs 2005;16:167-174. (Pubitemid 40250612)